NASDAQ:SNNA - Sienna Biopharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.00 -0.10 (-4.76 %) (As of 04/23/2019 04:00 PM ET)Previous Close$2.10Today's Range$1.99 - $2.1552-Week Range$1.86 - $20.00Volume246,323 shsAverage Volume336,529 shsMarket Capitalization$60.75 millionP/E RatioN/ADividend YieldN/ABeta3.64 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. Receive SNNA News and Ratings via Email Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNNA Previous Symbol CUSIPN/A CIK1656328 Webwww.siennabio.com Phone818-629-2256Debt Debt-to-Equity Ratio1.13 Current Ratio2.07 Quick Ratio2.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.57Profitability EPS (Most Recent Fiscal Year)($3.59) Net Income$-73,470,000.00 Net MarginsN/A Return on Equity-144.44% Return on Assets-59.83%Miscellaneous Employees58 Outstanding Shares30,375,000Market Cap$60.75 million Next Earnings Date5/13/2019 (Estimated) OptionableNot Optionable Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions What is Sienna Biopharmaceuticals' stock symbol? Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA." How were Sienna Biopharmaceuticals' earnings last quarter? Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.83) by $0.10. View Sienna Biopharmaceuticals' Earnings History. When is Sienna Biopharmaceuticals' next earnings date? Sienna Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Sienna Biopharmaceuticals. What price target have analysts set for SNNA? 2 Wall Street analysts have issued twelve-month price objectives for Sienna Biopharmaceuticals' stock. Their predictions range from $17.00 to $45.00. On average, they expect Sienna Biopharmaceuticals' stock price to reach $31.00 in the next year. This suggests a possible upside of 1,450.0% from the stock's current price. View Analyst Price Targets for Sienna Biopharmaceuticals. What is the consensus analysts' recommendation for Sienna Biopharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sienna Biopharmaceuticals. Has Sienna Biopharmaceuticals been receiving favorable news coverage? Media headlines about SNNA stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sienna Biopharmaceuticals earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. Who are some of Sienna Biopharmaceuticals' key competitors? Some companies that are related to Sienna Biopharmaceuticals include Urovant Sciences (UROV), Strongbridge Biopharma (SBBP), Cerecor (CERC), Protagonist Therapeutics (PTGX), Calithera Biosciences (CALA), TapImmune (MRKR), Dova Pharmaceuticals (DOVA), Aclaris Therapeutics (ACRS), Molecular Templates (MTEM), resTORbio (TORC), Syros Pharmaceuticals (SYRS), Xenon Pharmaceuticals (XENE), Athersys (ATHX), Concert Pharmaceuticals (CNCE) and Ardelyx (ARDX). What other stocks do shareholders of Sienna Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sienna Biopharmaceuticals investors own include Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), ZEALAND PHARMA/S (ZEAL), Clearside Biomedical (CLSD), MOTIF BIO PLC/S (MTFB), Pieris Pharmaceuticals (PIRS) and Rigel Pharmaceuticals (RIGL). Who are Sienna Biopharmaceuticals' key executives? Sienna Biopharmaceuticals' management team includes the folowing people: Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)Mr. John W. Smither, Chief Financial Officer (Age 66)Mr. Majed Kheir, VP of Operations (Age 41)Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49)Mr. Sean Andrews, Sr. Director of Investor Relations When did Sienna Biopharmaceuticals IPO? (SNNA) raised $64 million in an IPO on Thursday, July 27th 2017. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of Sienna Biopharmaceuticals? Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sienna Biopharmaceuticals' stock price today? One share of SNNA stock can currently be purchased for approximately $2.00. How big of a company is Sienna Biopharmaceuticals? Sienna Biopharmaceuticals has a market capitalization of $60.75 million. The company earns $-73,470,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Sienna Biopharmaceuticals employs 58 workers across the globe. What is Sienna Biopharmaceuticals' official website? The official website for Sienna Biopharmaceuticals is http://www.siennabio.com. How can I contact Sienna Biopharmaceuticals? Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected] MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 202 (Vote Outperform)Underperform Votes: 212 (Vote Underperform)Total Votes: 414MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/23/2019 by MarketBeat.com StaffFeatured Article: What is a Market Correction?